Donepezil for behavioural disorders associated with Lewy bodies: A case series

International Journal of Geriatric Psychiatry

Volumn 15, Issue 4, 2000, Pages 338-345

  Lanctôt, Krista L ^a,b   Herrmann, Nathan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Behavioural disorders; Dementia with Lewy bodies; Donepezil

Indexed keywords

DONEPEZIL;

AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; BEHAVIOR DISORDER; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DEPRESSION; DIAPHORESIS; DROWSINESS; FEMALE; HALLUCINATION; HUMAN; LEWY BODY; MALE; MENTAL IRRITATION; SIDE EFFECT; SYNCOPE;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; LEWY BODY DISEASE; MALE; NOOTROPIC AGENTS; PIPERIDINES; SOCIAL BEHAVIOR DISORDERS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034022472     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(200004)15:4<338::AID-GPS119>3.0.CO;2-U     Document Type: Article

References (22)

1. Aarsland, D., Bronnick, K. and Karlsen, K. (1999) Donepezil for dementia with Lewy bodies: a case study. Int. J. Geriatr. Psychiat. 14, 69-72.
2. Allen, R. L., Walker, A., D'Ath, P. J. and Katona, C. L. E. (1995) Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 346, 185.
3. Ballard, C. G., O'Brien, J., Lowery, K. et al (1998) A prospective study of dementia with Lewy bodies. Age Ageing 27, 631-636.
4. Bodick, N. C., Offen, W. W., Levey, AI. et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465-473.
5. Burns, A., Rossor, M., Hecker, J. et al. (1999) The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement. Geriatr. Cogn. Disord. 10, 237-244.
6. Cummings, J. L., Gorman, D. G. and Shapira, J. (1993) Physostigmine ameliorates the delusions of Alzheimer's disease. Biol. Psychiat. 35, 536-541.
7. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994) The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
8. Folstein, M. F. and Folstein, S. E. (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 12, 189-198.
9. Holmes, C., Cairns, N., Lantos, P. and Mann, A. (1999) Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br. J. Psychiat. 174, 45-50.
10. Kaufer, D. I., Cummings, J. L. and Christine, D. (1996) Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J. Geriatr. Psychiat. Neurol. 9, 1-6.
11. Kaufer, D. I., Catt, K. E., Lopez, O. L. and DeKosky, S. T. (1998) Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 51, 1512.
12. Levy, R., Eagger, S., Griffiths, M. et al. (1994) Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 343, 176.
13. Litvan, I., MacIntyre, A., Goetz, C. G. et al. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies. A clinicopathologic study. Arch. Neurol. 55, 969-978.
14. McKeith, I., Galasko, D., Kosaka, K. et al. (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology 47, 1113-1124.
15. Morris, J. C., Cyrus, P. A., Orazem, J. et al. (1998) Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 50, 1222-1230.
16. Perry, E. K. and Perry, R. H. (1995) Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain & Cognition 28, 240-258.
17. Perry, E. K., Marshall, E., Kerwin, J. et al. (1991) Evidence of monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J. Neurochem. 55, 1454-1456.
18. Raskind, M. A., Sadowsky, C. H., Sigmund, W. R., Beitler, P. J. and Auster, S. B. (1997) Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch. Neurol. 54, 836-840.
19. Rogers, S. L., Doody, R. S., Mohs, R. C. and Friedhoff, L. T. (1998a) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Int. Med. 158, 1021-1031.
20. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. and Friedhoff, L. T. (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50, 136-145.
21. Shea, C., MacKight, C. and Rockwood, K. (1998) Donepezil for treatment of dementia with Lewy Bodies: a case series of nine patients. Int. Psychogeriat. 10, 229-238.
22. Wengel, S. P., Roccaforte, W. H. and Burke, W. J. (1998) Donepezil improves symptoms of delirium in dementia: implications for future research. J. Geriatr. Psychiat. Neurol. 11, 159-161.